Company Filing History:
Years Active: 2003-2006
Title: Thomas J Mitchell: Innovator in Alzheimer's Disease Research
Introduction
Thomas J Mitchell is a notable inventor based in Newark, DE (US), recognized for his contributions to the field of Alzheimer's disease research. He holds two patents that focus on innovative methods for monitoring and screening compounds related to the beta-amyloid precursor protein (APP). His work is significant in the ongoing battle against Alzheimer's disease, a condition that affects millions worldwide.
Latest Patents
Mitchell's latest patents include "Epitope-tagged beta-amyloid precursor protein and DNA encoding the same" and "Method for screening compounds to identify beta-amyloid production modulators." The first patent is directed towards methods and compositions for monitoring the processing of epitope-tagged beta-APP. This invention is particularly relevant for evaluating responses of cells expressing epitope-tagged beta-APP to therapies aimed at treating disorders associated with altered metabolism of APP, including Alzheimer's disease. The second patent also focuses on similar methodologies for screening potential drugs that could modulate beta-amyloid production, further contributing to the understanding and treatment of Alzheimer's disease.
Career Highlights
Thomas J Mitchell is currently associated with Bristol-Myers Squibb Company, where he continues to advance research in the field of neurodegenerative diseases. His work at this prominent pharmaceutical company allows him to collaborate with other experts and contribute to significant advancements in drug development.
Collaborations
One of his notable collaborators is Dietmar A Seiffert, with whom he has worked closely on various projects related to Alzheimer's disease and beta-amyloid research.
Conclusion
Thomas J Mitchell's innovative work in the field of Alzheimer's disease research, particularly through his patents, showcases his commitment to finding solutions for this challenging condition. His contributions are vital in the ongoing efforts to develop effective therapies for Alzheimer's disease.